Artivion reported a 4% increase in revenue on a GAAP basis for Q4 2024, reaching $97.3 million, and a 10% increase for the full year 2024, reaching $388.5 million. The company achieved positive free cash flow and significant growth in adjusted EBITDA, while also making strides in clinical and regulatory initiatives, including receiving Humanitarian Device Exemption for AMDS.
Fourth quarter 2024 revenue increased by 4% on a GAAP basis to $97.3 million compared to $93.7 million in Q4 2023.
Full year 2024 revenue increased by 10% on a GAAP basis to $388.5 million compared to $354.0 million in 2023.
Adjusted EBITDA increased by 15% to $17.6 million in Q4 2024 and by 32% to $71.3 million for the full year 2024.
Net loss for Q4 2024 was $(16.5) million, or $(0.39) per fully diluted share, while non-GAAP net income was $0.2 million, or $0.00 per fully diluted share.
Artivion expects revenues for the full year 2025 to be in the range of $420 million to $435 million, representing growth of 10% to 14% on a constant currency basis compared to 2024. Adjusted EBITDA growth is expected to be between 18% and 28% for the full year 2025 compared to 2024, resulting in an expected range of $84 million to $91 million for 2025.
Analyze how earnings announcements historically affect stock price performance